| Sign In to gain access to subscriptions and/or personal tools. |
Toxicoproteomics: Serum Proteomic Pattern Diagnostics for Early Detection of Drug Induced Cardiac Toxicities and CardioprotectionFDA-NCI Clinical Proteomics Program, Office of Cell and Gene Therapies, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA, petricoin{at}cber.fda.gov
FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, USA
Division of Applied Pharmacology Research, Center for Drug Evaluation and Research, Food and Drug Administration, Laurel, Maryland, USA
FDA-NCI Clinical Proteomics Program, Office of Cell and Gene Therapies, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, USA
FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, USA
Division of Applied Pharmacology Research, Center for Drug Evaluation and Research, Food and Drug Administration, Laurel, Maryland, USA
Division of Applied Pharmacology Research, Center for Drug Evaluation and Research, Food and Drug Administration, Laurel, Maryland, USA
Correlogic Systems, Inc., Bethesda, Maryland, USA
NCI Biomedical Proteomics Program, Analytical Chemistry Laboratory, Mass Spectrometry Center, SAIC Frederick, Inc., SAIC-NCI, Frederick, Maryland, USA
NCI Biomedical Proteomics Program, Analytical Chemistry Laboratory, Mass Spectrometry Center, SAIC Frederick, Inc., SAIC-NCI, Frederick, Maryland, USA
FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, USA
Division of Applied Pharmacology Research, Center for Drug Evaluation and Research, Food and Drug Administration, Laurel, Maryland, USA Proteomics is more than just generating lists of proteins that increase or decrease in expression as a cause or consequence of pathology. The goal should be to characterize the information flow through the intercellular protein circuitry which communicates with the extracellular microenvironment and then ultimately to the serum/plasma macroenvironment. The nature of this information can be a cause, or a consequence, of disease and toxicity based processes as cascades of reinforcing information percolate through the system and become reflected in changing proteomic information content of the circulation. Serum Proteomic Pattern Diagnostics is a new type of proteomic platform in which patterns of proteomic signatures from high dimensional mass spectrometry data are used as a diagnostic classifier. While this approach has shown tremendous promise in early detection of cancers, detection of drug-induced toxicity may also be possible with this same technology. Analysis of serum from rat models of anthracycline and anthracenedione induced cardiotoxicity indicate the potential clinical utility of diagnostic proteomic patterns where low molecular weight peptides and protein fragments may have higher accuracy than traditional biomarkers of cardiotoxicity such as troponins. These fragments may one day be harvested by circulating nanoparticles designed to absorb, enrich and amplify the diagnostic biomarker repertoire generated even at the critical initial stages of toxicity.
Key Words: Mass spectrometry • toxicoproteomics • proteomics • cardiotoxicity • patterns • nanotechnology.
Toxicologic Pathology, Vol. 32, No. 1 suppl,
122-130 (2004) This article has been cited by other articles:
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
|
Sign In to gain access to subscriptions and/or personal tools.
